{"id":"https://openalex.org/W2117239552","doi":"https://doi.org/10.1517/14656566.2.11.1795","title":"Angiotensin II receptor blockers for the treatment of hypertension","display_name":"Angiotensin II receptor blockers for the treatment of hypertension","publication_year":2001,"publication_date":"2001-11-01","ids":{"openalex":"https://openalex.org/W2117239552","doi":"https://doi.org/10.1517/14656566.2.11.1795","mag":"2117239552","pmid":"https://pubmed.ncbi.nlm.nih.gov/11825317"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.2.11.1795","doi":"https://doi.org/10.1517/14656566.2.11.1795","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2.11.1795","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110061441","display_name":"Sharon See","orcid":"https://orcid.org/0000-0002-4192-3894","observed_orcids":["https://orcid.org/0000-0002-4192-3894"]},"institutions":[{"id":"https://openalex.org/I142823887","display_name":"St. John's University","ror":"https://ror.org/00bgtad15","country_code":"US","type":"education","lineage":["https://openalex.org/I142823887"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sharon See","raw_affiliation_strings":["St. John's University College of Pharmacy, 8000 Utopia Parkway, NY 11439, USA. sees@stjohns.edu","Assistant Clinical Professor, St. John\u2019s University College of Pharmacy, 8000 Utopia Parkway, NY 11439, USA, Tel.: +1 718 990 2474"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. John's University College of Pharmacy, 8000 Utopia Parkway, NY 11439, USA. sees@stjohns.edu","institution_ids":["https://openalex.org/I142823887"]},{"raw_affiliation_string":"Assistant Clinical Professor, St. John\u2019s University College of Pharmacy, 8000 Utopia Parkway, NY 11439, USA, Tel.: +1 718 990 2474","institution_ids":["https://openalex.org/I142823887"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5110061441"],"corresponding_institution_ids":["https://openalex.org/I142823887"],"apc_list":null,"apc_paid":null,"fwci":0.3159,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.42219388,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"2","issue":"11","first_page":"1795","last_page":"1804"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.11940000206232071,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":1.0},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.875},{"id":"https://openalex.org/keywords/renin-angiotensin-aldosterone-system","display_name":"renin-angiotensin-aldosterone system","score":0.9309999942779541},{"id":"https://openalex.org/keywords/renal-protection","display_name":"renal protection","score":0.9049999713897705},{"id":"https://openalex.org/keywords/congestive-heart-failure","display_name":"congestive heart failure","score":0.9459999799728394},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8050000071525574},{"id":"https://openalex.org/keywords/diabetic-nephropathy","display_name":"diabetic nephropathy","score":0.9959999918937683},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.8140000104904175},{"id":"https://openalex.org/keywords/irbesartan","display_name":"irbesartan","score":0.8349999785423279},{"id":"https://openalex.org/keywords/losartan","display_name":"losartan","score":0.9829999804496765},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":0.9789999723434448},{"id":"https://openalex.org/keywords/ace-inhibitor-intolerance","display_name":"ACE inhibitor intolerance","score":0.6959999799728394},{"id":"https://openalex.org/keywords/antihypertensive-therapy","display_name":"antihypertensive therapy","score":0.6949999928474426},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.49799999594688416}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9405741691589355},{"id":"https://openalex.org/C2780259554","wikidata":"https://www.wikidata.org/wiki/Q947266","display_name":"Irbesartan","level":3,"score":0.9257708787918091},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.6734548807144165},{"id":"https://openalex.org/C2780288358","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan","level":4,"score":0.6607438325881958},{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.5881727337837219},{"id":"https://openalex.org/C2779922275","wikidata":"https://www.wikidata.org/wiki/Q1129105","display_name":"Diabetic nephropathy","level":3,"score":0.5513225197792053},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5505148768424988},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.542557954788208},{"id":"https://openalex.org/C2781184683","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Nephropathy","level":3,"score":0.5199267268180847},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4645768105983734},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.44146019220352173},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4277498722076416},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.2817828059196472},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2183651626110077}],"mesh":[{"descriptor_ui":"D000804","descriptor_name":"Angiotensin II","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D044140","descriptor_name":"Receptor, Angiotensin, Type 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/14656566.2.11.1795","doi":"https://doi.org/10.1517/14656566.2.11.1795","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2.11.1795","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:11825317","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11825317","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W108493947","https://openalex.org/W1973222295","https://openalex.org/W1984215242","https://openalex.org/W1996228728","https://openalex.org/W2003670762","https://openalex.org/W2009597300","https://openalex.org/W2010713554","https://openalex.org/W2039665384","https://openalex.org/W2044773944","https://openalex.org/W2056976690","https://openalex.org/W2076116711","https://openalex.org/W2077764615","https://openalex.org/W2080742733","https://openalex.org/W2084191761","https://openalex.org/W2084271364","https://openalex.org/W2085653849","https://openalex.org/W2100082183","https://openalex.org/W2100767767","https://openalex.org/W2103745044","https://openalex.org/W2107511879","https://openalex.org/W2128975519","https://openalex.org/W2165077933","https://openalex.org/W2167732511","https://openalex.org/W2168725185","https://openalex.org/W2318174853","https://openalex.org/W2319971694","https://openalex.org/W2323072331","https://openalex.org/W2342067247","https://openalex.org/W2409561729","https://openalex.org/W2414167269","https://openalex.org/W3021250193","https://openalex.org/W3022929210","https://openalex.org/W3190265201"],"related_works":["https://openalex.org/W2470454545","https://openalex.org/W4292003902","https://openalex.org/W2411298426","https://openalex.org/W1886334003","https://openalex.org/W2433531004","https://openalex.org/W2063772539","https://openalex.org/W1710798854","https://openalex.org/W2052507582","https://openalex.org/W2154361372","https://openalex.org/W2411299209"],"abstract_inverted_index":{"The":[0,49,146,183,215],"rising":[1],"incidence":[2,249],"of":[3,25,46,62,69,83,128,137,149,167,172,185,207,226,250,274],"stroke,":[4],"congestive":[5],"heart":[6],"failure":[7],"(CHF)":[8],"and":[9,23,64,139,182,189,198,233,245,252,270,278],"end":[10],"stage":[11],"renal":[12,279],"disease":[13],"(ESRD)":[14],"has":[15],"signalled":[16],"a":[17,31,40,56,131,239,247],"need":[18,32],"to":[19,29,43,59,86,125,159,222,255],"increase":[20],"awareness,":[21],"treatment":[22],"control":[24],"hypertension.":[26],"There":[27],"continues":[28],"be":[30,66,107],"for":[33,109],"effective":[34],"antihypertensive":[35],"medications":[36],"since":[37],"hypertension":[38,63],"is":[39,55],"major":[41],"precursor":[42],"various":[44],"forms":[45],"cardiovascular":[47],"disease.":[48,280],"renin-angiotensin":[50],"(AT)":[51],"aldosterone":[52],"system":[53],"(RAAS)":[54],"key":[57],"component":[58],"the":[60,79,96,126,135,145,150,165,170,204,223,260,263,272],"development":[61],"can":[65],"one":[67],"target":[68],"drug":[70],"therapy.":[71],"Angotensin":[72],"II":[73],"(ATII)":[74],"receptor":[75,97],"blockers":[76],"(ARBs)":[77],"are":[78,123,242],"most":[80],"recent":[81],"class":[82],"agents":[84],"available":[85],"treat":[87],"hypertension,":[88,269],"which":[89],"work":[90],"by":[91,92],"inhibiting":[93],"ATII":[94],"at":[95],"level.":[98],"Currently,":[99],"national":[100],"consensus":[101],"guidelines":[102],"recommend":[103],"that":[104,228],"ARBs":[105,208,229,241,275],"should":[106],"reserved":[108],"hypertensive":[110],"patients":[111,210],"who":[112],"cannot":[113],"tolerate":[114],"angiotensin":[115],"converting":[116],"enzyme":[117],"(ACE)":[118],"inhibitors":[119],"(ACEIs).":[120],"ARBs,":[121,264],"however,":[122],"moving":[124],"forefront":[127],"therapy":[129],"with":[130,156,177,194,211],"promising":[132],"role":[133,273],"in":[134,154,175,192,209,235,268,276],"area":[136],"renoprotection":[138],"CHF.":[140],"Recent":[141],"trials":[142],"such":[143],"as":[144],"Renoprotective":[147],"Effect":[148,166],"Angiotensin-Receptor":[151],"Antagonist":[152],"Irbesartan":[153,168],"Patients":[155,176,193],"Nephropathy":[157,174,199],"Due":[158],"Type":[160,178,195,212],"2":[161,179,196,213],"Diabetes":[162,180,197],"Trial":[163,219],"(IDNT),":[164],"on":[169,187],"Development":[171],"Diabetic":[173],"(IRMA2),":[181],"Effects":[184],"Losartan":[186],"Renal":[188],"Cardiovascular":[190],"Outcomes":[191],"(RENAAL)":[200],"study":[201],"have":[202,246],"demonstrated":[203],"renoprotective":[205],"effects":[206],"diabetes.":[214],"Valsartan":[216],"Heart":[217],"Failure":[218],"(Val-HeFT)":[220],"adds":[221],"growing":[224],"body":[225],"evidence":[227],"may":[230],"improve":[231],"morbidity":[232],"mortality":[234],"CHF":[236,277],"patients.":[237],"As":[238],"class,":[240],"well":[243],"tolerated":[244],"lower":[248],"cough":[251],"angioedema":[253],"compared":[254],"ACEIs.":[256],"This":[257],"article":[258],"reviews":[259],"differences":[261],"among":[262],"existing":[265],"efficacy":[266],"data":[267],"explores":[271]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}